Natera's Signatera Becomes First PMDA-Approved MRD Test in Japan for Colorectal Cancer
核心洞察
Natera's Signatera (搜索) test received PMDA approval in Japan for molecular residual disease detection in colorectal cancer (搜索), marking the first regulatory-approved MRD test in the country.
The company plans to commercially launch Signatera (搜索) in Japan by the end of 2026, expanding its international footprint.
The approval follows Signatera (搜索)'s inclusion in NCCN guidelines for muscle-invasive bladder cancer (搜索), prompting BTIG analysts to raise their price target to $270.
Shares of genetic testing company Natera (NTRA) jumped 7.7% in morning trading after the company announced that its Signatera (搜索) test received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The approval, specific to use in patients with colorectal cancer (搜索), establishes Signatera as the first PMDA-approved molecular residual disease (MRD) test in Japan.
MRD tests are designed to detect small numbers of cancer cells that may remain in the body during or after treatment, offering clinicians a tool to monitor treatment response and assess recurrence risk. Natera plans to launch the test commercially in Japan by the end of 2026, marking a significant step in the company's international expansion strategy.
The Japanese regulatory milestone comes on the heels of another positive development for Signatera (搜索). The day prior, analysts at BTIG raised their price target on Natera stock to $270 from $250, following the test's inclusion in National Comprehensive Cancer Network (NCCN) guidelines for muscle-invasive bladder cancer (搜索). This dual momentum—regulatory approval in a major Asian market and expanded guideline recognition in the U.S.—underscores the growing clinical adoption of Signatera across multiple tumor types.
Natera's operational performance has demonstrated robust growth. In its most recent quarterly results, the company posted first-quarter 2026 revenue of $696.6 million, representing a 38.8% year-over-year increase that beat analysts' expectations. Test volumes rose 18.5% compared to the same period last year, reflecting strong market demand and operational momentum.
Despite the top-line strength, profitability remains a point of focus for investors. The company's GAAP loss widened to $0.60 per share from $0.50 per share in the prior-year quarter, missing Wall Street's consensus estimate of a $0.55 loss per share. The widening loss, even as sales surged, has raised questions about Natera's timeline to sustained profitability. However, analyst consensus points toward the company reaching profitability by fiscal year 2028, supported by upward earnings revisions and margin improvements.
Natera maintains a conservative balance sheet with a debt-to-equity ratio of 0.13 and over $1 billion in cash, providing liquidity to fund its expansion initiatives. The company's shares have risen 11% since the beginning of the year, trading near their 52-week high.
The Signatera (搜索) approval in Japan represents a strategic foothold in Asia's second-largest pharmaceutical market and positions Natera to address an unmet need in colorectal cancer (搜索) monitoring—one of the most prevalent cancers in Japan. As the first company to secure PMDA clearance for an MRD test, Natera gains a first-mover advantage that could facilitate broader adoption and potential future approvals in additional indications.